Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells (STOP CAP)

This study has been completed.
Information provided by:
Emory University
ClinicalTrials.gov Identifier:
First received: September 12, 2005
Last updated: June 26, 2009
Last verified: June 2009

September 12, 2005
June 26, 2009
September 2004
March 2008   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00166036 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells: Comparison of Atorvastatin With Pravastatin

Individuals with a high cholesterol level, diabetes or metabolic syndrome (collection of abnormalities such as high blood pressure, high triglyceride levels [fat], obesity, high blood glucose level) have an increased risk of developing a hardening of the arteries and heart disease.

A group of medications called statins, commonly used worldwide to lower cholesterol levels, are known to reduce the risk of heart disease through their effects on reducing cholesterol levels. These medications also have effects beyond the lowering of cholesterol that may help mediate their beneficial effects on the heart and blood vessels.

These include a reduced production of molecules that harm the arteries such as reactive oxygen species (ROS) and increasing the number of stem cells that help repair vessels, called endothelial progenitor cells (EPCs).

Recent studies have shown that different statins might have different effects on protecting people from developing heart disease. These differences may be due to differences in these non-cholesterol lowering processes, and are the subject of this study.

Standard of Care:

The two statins that will be used in this study, pravastatin (Pravachol ®) and atorvastatin (Lipitor®), are approved for use in people with a high cholesterol level or heart disease. These medications are generally very well tolerated with minimal side effects. They are not approved for use in patients to increase the level of EPCs or to reduce the production of ROS, and therefore are considered experimental for this indication. Currently there are no drugs that are specifically approved for these indications.

How the Problem Will be Studied:

These statins will be given to patients who have high cholesterol and either diabetes or the metabolic syndrome once a day for 12 weeks. We, the investigators at Emory, will measure the level of EPCs and ROS before and during the administration of the statin. We will also investigate how well the blood vessels dilate in response to these medications by performing an imaging study of the forearm artery using ultrasound.

The study is blinded and there is an equal chance of receiving either atorvastatin 10mg or pravastatin 80mg which are likely to lower cholesterol level by a similar amount.

How Research Will Advance Scientific Knowledge:

The goal of this study is to determine if atorvastatin will increase the number of circulating EPCs and reduce the production of ROS more than pravastatin. This may help explain the differences between these drugs that have been observed in some recently published trials.

Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Diabetes Mellitus
  • Metabolic Syndrome X
  • Hypercholesterolemia
  • Drug: Atorvastatin
  • Drug: Pravastatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
April 2009
March 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males or females without child bearing potential aged 21-80 years
  • Fasting low-density lipoprotein (LDL) level > 120mg/dL.
  • Either known to be diabetic or have at least 3 components of metabolic syndrome that are defined below:

    • Hypertension defined as blood pressure (BP) > 140 systolic or > 90 mmHg diastolic, or stable medical therapy for documented hypertension;
    • Fasting glucose > 110 mg/dL;
    • Waist > 40 inches in males, and > 35 inches in females;
    • Triglycerides > 150mg/dL; or
    • High-density lipoprotein (HDL) cholesterol < 40 mg/dL in males and < 50 mg/dL in females.
  • Able to provide written informed consent
  • Non-smoker

Exclusion Criteria:

  • On any oral antioxidants or lipid lowering medications in the previous 8 weeks
  • Age < 21 or > 80 years
  • Premenopausal females with potential for pregnancy
  • LDL cholesterol level < 120 mg/dl
  • Initiation or change in dose of any concomitant medical therapy within 2 months before the study
  • Uncontrolled hypertension with BP > 180 mmHg systolic and > 120 mmHg diastolic
  • Current smoker
  • Previous intolerance or allergy to statins
  • Acute infection in previous 4 weeks
  • History of substance abuse
  • Uninterpretable Brachial Artery Reactivity Study
  • Current neoplasm
  • Chronic renal failure (creatinine > 2.5 mg/dL) or liver failure (liver enzymes > 2X normal)
  • Acute coronary syndrome, heart failure, cerebrovascular accident (CVA), or coronary intervention within 3 months
  • Known aortic stenosis, hypertrophic cardiomyopathy, or symptomatic heart failure.
  • Inability to give informed consent
  • Inability to return to Emory for follow-up
21 Years to 80 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
Arshed A Quyyumi, MD, Emory University
Emory University
Not Provided
Principal Investigator: Arshed A Quyyumi, MD Emory University
Emory University
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP